

Federica Tomao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7055375/publications.pdf>

Version: 2024-02-01

130
papers

2,874
citations

159585

30
h-index

223800

46
g-index

131
all docs

131
docs citations

131
times ranked

4790
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent) Tj ETQq1 1 0.784314 rgBT /Overlock 505-513.	1.4	35
2	CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset. <i>Cancers</i> , 2022, 14, 2739.	3.7	19
3	Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	3
4	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250.	2.5	5
5	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	2.4	16
6	Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?. <i>Cancers</i> , 2021, 13, 4061.	3.7	5
7	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 769280.	2.8	45
8	Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13650.	4.1	9
9	Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors. <i>Oncology</i> , 2020, 98, 10-15.	1.9	5
10	Intraperitoneal Chemotherapy: A Strategy for the Treatment of Refractory Ascites in Recurrent Endometrial Cancer Patients â€“ Three Case Reports and Review of the Literature. <i>Oncology</i> , 2020, 98, 98-101.	1.9	2
11	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel antiâ€HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	5.1	4
12	Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 9-20.	2.3	37
13	Targeting cervical cancer: Is there a role for poly (ADPâ€ribose) polymerase inhibition?. <i>Journal of Cellular Physiology</i> , 2020, 235, 5050-5058.	4.1	17
14	Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 105-111.	2.3	13
15	Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL). <i>Cancers</i> , 2020, 12, 2841.	3.7	10
16	<p>First-Line Treatment Âwith OlaparibÂfor Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5479-5489.	1.9	3
17	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. <i>ESMO Open</i> , 2020, 5, e000827.	4.5	18
18	The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. <i>Oncology</i> , 2020, 98, 807-813.	1.9	4

#	ARTICLE	IF	CITATIONS
19	The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 283-297.	0.7	3
20	Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?. Journal of Clinical Medicine, 2020, 9, 1721.	2.4	43
21	<p>Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches</p>. OncoTargets and Therapy, 2020, Volume 13, 6109-6129.	2.0	54
22	Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review. Oncology, 2020, 98, 195-201.	1.9	13
23	Endometriosis and Pregnancy: A Single Institution Experience. International Journal of Environmental Research and Public Health, 2020, 17, 401.	2.6	24
24	Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial. Lancet Oncology, The, 2020, 21, 616-617.	10.7	2
25	Fertility and reproduction in breast cancer patients. Breast Cancer Research and Treatment, 2020, 182, 245-246.	2.5	0
26	Uterine irradiation as a determinant of infertility and pregnancy losses in young cancer survivors. Ecancermedicalscience, 2020, 14, 1032.	1.1	2
27	Imaging strategy in recurrent ovarian cancer: a practical review. Abdominal Radiology, 2019, 44, 1091-1102.	2.1	16
28	Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer. Expert Opinion on Investigational Drugs, 2019, 28, 667-673.	4.1	1
29	Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treatment Reviews, 2019, 80, 101909.	7.7	63
30	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. Journal of Hematology and Oncology, 2019, 12, 111.	17.0	93
31	Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. Cancers, 2019, 11, 1641.	3.7	22
32	The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life. Oncology, 2019, 97, 306-310.	1.9	8
33	Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions. Journal of Clinical Oncology, 2019, 37, 3168-3169.	1.6	3
34	Fertility Preservation and Reproductive Health in Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e389-e390.	2.0	1
35	Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?. Gynecologic Oncology, 2019, 154, 138-143.	1.4	13
36	Paclitaxel and Alisertib in Recurrent Ovarian Cancer. JAMA Oncology, 2019, 5, 909.	7.1	2

#	ARTICLE	IF	CITATIONS
37	Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 935-936.	1.6	1
38	Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 254.	2.4	27
39	The age-adjusted Charlson comorbidity index as a predictor of survival in surgically treated vulvar cancer patients. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e6.	2.2	15
40	The impact of CO2 laser for treatment of Bartholinâ€™s gland cyst or abscess on female sexual function: a pilot study. <i>Gynecological Endocrinology</i> , 2019, 35, 150-154.	1.7	4
41	BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5572-5572.	1.6	0
42	Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 505-513.	2.5	21
43	Complete remission of cerebral endometriosis with dienogest: a case report. <i>Gynecological Endocrinology</i> , 2018, 34, 837-839.	1.7	12
44	Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 650-660.	0.8	65
45	Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 7-14.	7.7	51
46	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	4.1	17
47	Progesterone therapy in endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 362-363.	1.3	1
48	Fertility preservation in ovarian tumours. <i>Ecancermedalscience</i> , 2018, 12, 885.	1.1	16
49	Fertility preservation in gynaecologic cancers. <i>Ecancermedalscience</i> , 2018, 12, 798.	1.1	16
50	Paclitaxel and Pazopanib in Ovarian Cancer. <i>JAMA Oncology</i> , 2018, 4, 1298.	7.1	4
51	Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. <i>European Radiology</i> , 2018, 28, 4849-4859.	4.5	100
52	Conization in Early Stage Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1001-1008.	2.5	34
53	Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1443-1455.	1.8	28
54	Niraparib in ovarian cancer: results to date and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 579-588.	3.2	29

#	ARTICLE	IF	CITATIONS
55	Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?. <i>Cancer</i> , 2017, 123, 3450-3459.	4.1	48
56	Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions. <i>Chemotherapy</i> , 2017, 62, 111-120.	1.6	33
57	Bevacizumab in ovarian cancer: A critical review of phase III studies. <i>Oncotarget</i> , 2017, 8, 12389-12405.	1.8	100
58	Pembrolizumab in Programmed Death Ligand 1-Positive Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3633-3633.	1.6	2
59	Secondary cytoreductive surgery: surgical approach to bulky aortic nodes, splenic metastases and mesenteric disease. <i>Giornale Italiano Di Ostetricia E Ginecologia</i> , 2017, 39, 36.	0.1	0
60	Update on fertility-sparing treatment in primary and recurrent endometrial cancer. <i>Giornale Italiano Di Ostetricia E Ginecologia</i> , 2017, 39, 16.	0.1	0
61	Risk-reducing Salpingo-oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. <i>Anticancer Research</i> , 2017, 37, 5241-5248.	1.1	11
62	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	2.5	4
63	Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy. <i>Oncology</i> , 2016, 91, 205-210.	1.9	25
64	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , 2016, 15, 1327-1336.	4.4	79
65	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	4.1	12
66	Quality of Life Effects of Ovarian Suppression in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 4188-4188.	1.6	1
67	Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. <i>Journal of Translational Medicine</i> , 2016, 14, 267.	4.4	65
68	Breast Cancer Risk After Ovarian Stimulation for In Vitro Fertilization. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1713.	7.4	0
69	Fertility-Sparing Options in Young Women with Cervical Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 5.	3.0	19
70	Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 31-49.	4.1	35
71	Special issues in fertility preservation for gynecologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 206-219.	4.4	51
72	Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells. <i>Anticancer Research</i> , 2016, 36, 5109-5116.	1.1	11

#	ARTICLE	IF	CITATIONS
73	Triple-negative breast cancer: new perspectives for targeted therapies. <i>OncoTargets and Therapy</i> , 2015, 8, 177.	2.0	109
74	Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review. <i>Gynecologic Oncology</i> , 2015, 137, 373-379.	1.4	24
75	Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3670-3670.	1.6	1
76	Triple-negative breast cancer: investigating potential molecular therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 55-75.	3.4	44
77	Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells. <i>Journal of Cancer</i> , 2014, 5, 301-310.	2.5	39
78	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. <i>Tumori</i> , 2014, 100, e309-e313.	1.1	0
79	Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Cancer</i> , 2014, 5, 398-405.	2.5	8
80	Emerging Biological Treatments for Uterine Cervical Carcinoma. <i>Journal of Cancer</i> , 2014, 5, 86-97.	2.5	51
81	Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. <i>OncoTargets and Therapy</i> , 2014, 7, 1223.	2.0	105
82	Angiogenesis and antiangiogenic agents in cervical cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 2237.	2.0	61
83	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti- α -Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 916-925.	4.1	21
84	Hot flushes in women with breast cancer: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 185-198.	2.4	4
85	Combination of Bevacizumab and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Some Observations About the AURELIA Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3580-3580.	1.6	9
86	Is Removing 9 Lymph Nodes a Correct Cutoff to Define Optimal Lymphadenectomy?: The Open Question of Lymph Node Count. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1358-1358.	2.5	2
87	Clinical use of fertility agents and risk of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 130-137.	2.0	3
88	Immunologic treatments for precancerous lesions and uterine cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 29.	8.6	39
89	Modified gluteal fold advancement V-Y flap for vulvar reconstruction after surgery for vulvar malignancies. <i>Gynecologic Oncology</i> , 2014, 132, 125-129.	1.4	35
90	Impaired uterine artery flow associated with the presence of ovarian endometrioma: preliminary results of a prospective study. <i>Journal of Ovarian Research</i> , 2014, 7, 1.	3.0	66

#	ARTICLE	IF	CITATIONS
91	Benign schwannoma in supraclavicular region: a false-positive lymph node recurrence of breast cancer suspected by PET scan. Archives of Gynecology and Obstetrics, 2014, 290, 583-586.	1.7	5
92	Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. Expert Opinion on Investigational Drugs, 2014, 23, 37-53.	4.1	15
93	Fertility drugs, reproductive strategies and ovarian cancer risk. Journal of Ovarian Research, 2014, 7, 51.	3.0	23
94	Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. Tumor Biology, 2014, 35, 8415-8424.	1.8	10
95	Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100).. Journal of Clinical Oncology, 2014, 32, e12005-e12005.	1.6	1
96	G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)?. Journal of Clinical Oncology, 2014, 32, e20672-e20672.	1.6	1
97	Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results. Current Drug Targets, 2014, 15, 1107-1120.	2.1	16
98	The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D).. Journal of Clinical Oncology, 2014, 32, e12000-e12000.	1.6	1
99	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. Tumori, 2014, 100, e309-13.	1.1	1
100	A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report. Journal of Medical Case Reports, 2013, 7, 161.	0.8	6
101	Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. Journal of Experimental and Clinical Cancer Research, 2013, 32, 48.	8.6	72
102	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. Journal of Experimental and Clinical Cancer Research, 2013, 32, 49.	8.6	15
103	Breast adenomyoepithelioma: a case report with malignant proliferation of epithelial and myoepithelial elements. World Journal of Surgical Oncology, 2013, 11, 285.	1.9	30
104	An Update of Laparoscopy in Cervical Cancer Staging: Is It a Useful Procedure?. Oncology, 2013, 85, 160-165.	1.9	15
105	Tumor-derived microvesicles: The metastasomes. Medical Hypotheses, 2013, 80, 75-82.	1.5	21
106	Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View. Journal of Clinical Oncology, 2013, 31, 166-167.	1.6	8
107	Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocrine-Related Cancer, 2013, 20, R233-R245.	3.1	39
108	Breast cancer risk after exposure to fertility drugs. Expert Review of Anticancer Therapy, 2013, 13, 149-157.	2.4	11

#	ARTICLE	IF	CITATIONS
109	Current status of bevacizumab in advanced ovarian cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 889.	2.0	11
110	Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 457.	2.0	12
111	Gonadotropin-Releasing Hormone Agonists for the Preservation of Ovarian Function During Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 3310-3311.	1.6	2
112	Intraperitoneal Chemotherapy by Ultrasound-Guided Direct Puncture in Recurrent Ovarian Cancer: Feasibility, Compliance, and Complications. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1069-1074.	2.5	11
113	Breast cancer metastatic to the pituitary gland: a case report. <i>World Journal of Surgical Oncology</i> , 2012, 10, 137.	1.9	29
114	Role of chemotherapy in the management of vulvar carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 25-39.	4.4	19
115	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 35-46.	4.4	27
116	Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIb cervical cancer patients after neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2011, 37, 364-369.	1.0	34
117	Epistaxis in Weekly Paclitaxel Regimen: Is it Really Related to Schedule?. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 77-78.	2.5	0
118	Phase II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 687-693.	2.3	8
119	Current role and safety profile of aromatase inhibitors in early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1253-1263.	2.4	29
120	Ovarian function, reproduction and strategies for fertility preservation after breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 1-12.	4.4	17
121	Emerging role of pemetrexed in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1727-1735.	2.4	14
122	Immunogenicity of Allo-Vesicle Carrying ERBB2 Tumor Antigen for Dendritic Cell-Based Anti-Tumor Immunotherapy. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 647-658.	2.1	30
123	MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 99.e1-99.e7.	1.3	40
124	The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site. <i>World Journal of Surgical Oncology</i> , 2008, 6, 116.	1.9	12
125	Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 52.	8.6	56
126	Late Breast Cancer Recurrence to the Uterine Cervix With a Review of the Literature. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 113-117.	1.4	11

#	ARTICLE	IF	CITATIONS
127	Axillary and subcutaneous breast metastases from rhinopharyngeal carcinoma: a case report and literature review. <i>Anticancer Research</i> , 2008, 28, 419-23.	1.1	2
128	Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. <i>Annals of Oncology</i> , 2007, 18, 722-729.	1.2	6
129	A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs. <i>Journal of Immunotherapy</i> , 2007, 30, 567-576.	2.4	26
130	A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. <i>BMC Cancer</i> , 2006, 6, 137.	2.6	17